Tangeretin induces apoptosis and cell cycle arrest in thyroid cancer cells.

Authors

Yun-Hee Jeoung, Hong Kyu Lee, Seung-Hyeon Ahn, Zeeshan Ahmad Bhutta, Kyung-Chul Choi

Published in

Toxicological research. Volume 41. Issue 5. Pages 477-488. Epub May 13, 2025.

Abstract

Thyroid cancer is a malignant tumor whose incidence is increasing worldwide. While thyroid cancer is treatable and curable, a small number of cases can become metastatic when cancer cells originating in the thyroid gland spread to other parts of the body through the bloodstream or lymphatic system. The most common treatments for thyroid cancer are resection and radioactive iodine therapy. However, these treatments have side effects, such as hypothyroidism and damage to normal non-cancerous cells. Tangeretin is a polymethoxylated flavone found in the peel of citrus plants and has biological activity, including antioxidant, anti-inflammatory, and anti-cancer effects. However, the effects of tangeretin on human thyroid cancer have not been investigated. In this study, the effects of tangeretin on cell proliferation and apoptosis of the thyroid cancer cell line SNU-790 were investigated. To prove the results of this study, A water-soluble tetrazolium salt (WST) assay, cell cycle arrest assay, annexin V/PI, DCF-DA, JC-10, and western blot were used. Treatment with tangeretin decreased SNU-790 cell viability and proliferation ability. Annexin V/PI staining showed that tangeretin increased apoptotic cell death. In the wound healing assay, the tangeretin treatment decreased the wound closure area. In addition, tangeretin treatment increased the level of reactive oxygen species (ROS) in the cytosolic of SNU-790. The JC-10 assay showed that the tangeretin treatment decreased the mitochondrial membrane potential (MMP). Western blot analysis revealed that treatment with tangeretin increased the expression of the tumor protein p53. In conclusion, these results indicated that tangeretin inhibited the progression of thyroid cancer in SNU-790 cells by inhibiting migration ability, inducing mitochondrial dysfunction, and mediating oxidative stress in SNU-790. Hence, this study provides experimental evidence that tangeretin could be a potential candidate for the management of thyroid cancer.

PMID:
40873537
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.